Leinco Technologies

Recombinant Human VEGF 165 Protein

Product Code:
 
LEI-V101
Product Group:
 
Recombinant Proteins
Host Type:
 
Human
Regulatory Status:
 
RUO
Shipping:
 
Ambient
Storage:
 
This lyophilized protein is stable for six to twelve months when stored desiccated at -20°C to -70°C. After aseptic reconstitution this protein may be stored at 2°C to 8°C for one month or at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. See Product Insert for exact lot specific storage instructions.
 

No additional charges, what you see is what you pay! *

CodeSizePrice
LEI-V101-10ug10 ug£534.00
Quantity:
LEI-V101-50ug50 ug£1,524.00
Quantity:
LEI-V101-500ug500 ug£3,629.00
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: US.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • References
  • Show All

Further Information

Format:
This recombinant protein was lyophilized from a 0.2 um filtered solution in 35% acetonitrile (CH3CN) and 0.1% trifluoroacetic acid (TFA).
Formulation:
This recombinant protein was lyophilized from a 0.2 um filtered solution in 35% acetonitrile (CH3CN) and 0.1% trifluoroacetic acid (TFA).
Long Description:
Vascular endothelial growth factor (VEGF), a potent proangiogenic cytokine1 is the key signal used by oxygen-hungry cells to promote growth of blood vessels. It binds to specialized receptors on the surfaces of endothelial cells and directs them to build new vessels.2 VEGF are crucial regulators of vascular development during embryogenesis (vasculogenesis) and blood-vessel formation in the adult (angiogenesis). Abnormal VEGF function is associated with inflammatory diseases including atherosclerosis, and hyperthyroidism.3,4,5,6
Purity:
>97% by SDS-PAGE and analyzed by silver stain.
Target:
VEGF 165

References

1. Folkman, J. et al. (2008) FASEB J. 22: 37282. Goodsell, DS. et al. (2002) The Oncologist 7: 5693. Mugishima, H. et al. (2006) J Atheroscler Thromb. 13: 1304. Claesson-Welsh, L. et al. (2006) Exp Cell Res. 312: 5495. Claesson-Welsh, L. et al. (1999) Trends Biochem Sci. 28: 4886. Ellis, LM. et al. (2005) J Clin Oncol. 23: 1011